Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 6/20 | 0.60 |
| ▸ | MAOB | P27338 | 6/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.55 |
| ▸ | SDHA | P31040 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | CALML3 | P27482 | 1/20 | 0.55 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.49 |
| ▸ | F10 | P00742 | 8/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5833303 | 1.00 | MAOA (0.60) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL5833389 | 0.92 | MAOA (0.56) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL5833525 | 0.92 | MAOA (0.56) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL5834673 | 0.91 | MAOA (0.55) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL5834342 | 0.90 | MAOA (0.53) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL5834068 | 0.90 | F10 (0.61) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL5834064 | 0.90 | F10 (0.61) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL5833869 | 0.88 | MAOA (0.52) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL5834452 | 0.87 | MAOA (0.58) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL5834456 | 0.87 | MAOA (0.58) | MAOAMAOBPTGS1SDHALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7087629-B2 | Useful activity against Gram-positive pathogens and, in particular, against various strains exhibiting resistance to vancomycin and against E. faecium strains resistant to both aminoglycosides and clinically used beta-lactams | ASTRAZENECA AB (SE) | 2006-08-08 | — | — | US | disclosed |
| US-6734200-B1 | ANTIBIOTIC COMPOUNDS CONTAINING A SUBSTITUTED OXAZOLIDINONE RING; ACTIVITY AGAINST GRAM-POSITIVE PATHOGENS | ASTRAZENECA AB (SE) | 2004-05-11 | — | — | US | disclosed |
| US-20030207899-A1 | Heterocyclylaminomethyloxazo-lidinones as antibacterials | ASTRAZENECA AB (SE) | 2003-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207899-A1 | Heterocyclylaminomethyloxazo-lidinones as antibacterials | HDHD5, CYP8B1, LSS | MAOA 652/4885MAOB 705/4885PTGS1 1816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.